


OEHME, INA, DR.PHIL.NAT

GENERAL INFORMATION



Group Leader and Deputy Head of Department
CCU Pediatric Oncology
Hopp Children's Cancer Center Heidelberg (KiTZ)
Im Neuenheimer Feld 280
69120 Heidelberg
Germany

A02

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
2004	Dr. phil. nat. in Biochemistry and Pharmaceutical Chemistry
2000	Dipl. oec. troph. in Nutritional Science and Home Economics

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2019-present	Habilitandin at medical faculty, University of Heidelberg
2000-2004	PhD, Georg-Speyer-Haus & Johann- Wolfgang Goethe University, Frankfurt am Main
1994-2000	Academic studies, Justus-Liebig University Gießen

PROFESSIONAL EXPERIENCE

Year(s)	Education
2013-present	Group Leader and deputy head of the CCU Pediatric Oncology (Head: Prof. Dr. Olaf Witt), German Cancer Research Center (DKFZ)
2005-2008	Postdoctoral fellow, CCU Pediatric Oncology (Head: Prof. Dr. Olaf Witt), German Cancer Research Center (DKFZ)
2005	Postdoctoral fellow, Department of Biotechnology, University of Applied Science Lausitz, Senftenberg
2000-2004	Research Assistant, Georg-Speyer-Haus, Frankfurt am Main

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	
2016	IJMS Proffered Paper Prize, EACR conference "A Matter of Life or Death"
2014	Hector Research Award Onkology
2013	Kind-Philipp Award together with Dr. David Jones for the both best scientific works in pediatric oncology research in Germany
2004	Doctoral Thesis, Dr. phil. nat.
2000	Diploma Thesis in Nutritional Science and Home Economics at Justus-Liebig University, Gießen

SELECTED PUBLICATIONS

1. Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. J. Ridinger, E. Koeneke, F. R. Kolbinger, K. Koerholz, S. Mahboobi, L. Hellweg, N. Gunkel, A. K. Miller, H. Peterziel, P. Schmezer, A. Hamacher-Brady, O. Witt, **I. Oehme**, *Sci. Rep.* 8 (2018), 10039.
2. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. F. R. Kolbinger, E. Koeneke, J. Ridinger, T. Heimburg, M. Müller, T. Bayer, W. Sippl, M. Jung, N. Gunkel, A. K. Miller, F. Westermann, O. Witt, **I. Oehme**; *Arch. Tox.* 92 (2018) 2649-2664.
3. Shen J, Najafi S, Stäble S, Fabian J, Koeneke E, Kolbinger FR, Wrobel J, Meder B, Distel M, Heimburg T, Sippl W, Jung M, Peterziel H, Kranz D, Boutros M, Westermann F, Witt O, **Oehme I** (2018) A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. *Cell Death & Differentiation*. Dec; 25(12): 2053–2070.
4. Brocks D, Schmidt CR, Daskalakis M, Jang HS, Shah NM, Li D, Li J, Zhang B, Hou Y, Laudato S, Lipka DB, Schott J, Bierhoff H, Assenov Y, Helf M, Ressenrova A, Islam MS, Lindroth AM, Haas S, Essers M, Imbusch CD, Brors B, **Oehme**

- I, Witt O, Lubbert M, Mallm JP, Rippe K, Will R, Weichenhan D, Stoecklin G, Gerhauser C, Oakes CC, Wang T, Plass C (2017) DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. **Nat Genet** 49: 1052-1060.
5. Rettig I, Koeneke E, Trippel F, Mueller WC, Burhenne J, Kopp-Schneider A, Fabian J, Schober A, Fernekorn U, von Deimling A, Deubzer HE, Milde T, Witt O, **Oehme I** (2015) Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. **Cell Death Dis** 6: e1657.
 6. **Oehme I**, Linke JP, Böck BC, Milde T, Lodrini M, Hartenstein B, Wiegand I, Eckert C, Roth W, Kool M, Kaden S, Gröne HJ, Schulte JH, Lindner S, Hamacher-Brady A, Brady NR, Deubzer HE, Witt O. Histone deacetylase 10 promotes autophagy-mediated cell survival. **Proc Natl Acad Sci U S A** 2013; 110(28):E2592-2601.
 7. **Oehme, I.**, Deubzer, H.E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S.M., von Deimling, A., Fischer, M. and Witt, O. Histone Deacetylase 8 in Neuroblastoma Tumorigenesis. **Clinical Cancer Research** 2009; 15: 91-99